Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia

This resource was selected by SMI Adviser content partners and approved by the SMI Adviser clinical expert team for inclusion in the knowledge base.

This report summarizes the consensus from a roundtable that focused on defining and identifying treatment-resistant schizophrenia (TRS), pathways to treatment resistance, current treatments, unmet needs, and disease burden.


  • Was this Helpful ?
  • YesNo

Join our #MissionForBetter now

Sign up for our newsletter. We’ll let you know about new resources, education, and more.